Main Menu

Our Work

Amgen Inc. enjoys favorable settlement with Teva Pharmaceuticals

With support from Bates White, pharmaceutical manufacturer Amgen Inc. settled litigation with Teva Pharmaceuticals USA Inc. concerning Teva’s challenge to the validity of Amgen’s patents for Neupogen. The client obtained a favorable outcome through an agreement that prevents Teva from introducing its infringing drug in the United States before November 2013.


Amgen’s counsel retained Bates White and Professor Tomas Philipson of The University of Chicago to evaluate economic issues related to the injunction sought by Amgen to prevent Teva from marketing and selling its infringing drug, Neutroval, in the United States. Supported by Bates White, Dr. Philipson submitted an expert report that provided economic opinions concerning the application of the four factors identified in the US Supreme Court’s opinion in eBay v. MercExchange. Dr. Philipson’s opinion addressed the economic incentives created by Medicare’s reimbursement policies and the long-run repercussions of Teva’s anticipated infringing sales. Ultimately, Teva conceded that Amgen’s patents were valid and infringed. A court-approved settlement enjoined Teva from introducing Neutroval into the United States until November 2013—only one month before the patents at issue will expire.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.